Stat1/2 is involved in the inhibition of cell growth induced by U0126 in hela cells

Cellular and Molecular Biology

Volumn 55, Issue SUPP.1, 2009, Pages 1168-1174

  Zhao, L Y ^a   Huang, C ^a   Li, Z F ^b   Liu, L ^a   Ni, L ^a   Song, T S ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

AG490; Apoptosis; ERK1 2; HeLa cell; STAT1 2; U0126

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RAF PROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT2 PROTEIN; 1,3 BUTADIENE DERIVATIVE; ALPHA CYANO (3,4 DIHYDROXY) N BENZYLCINNAMIDE; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; NITRILE; STAT1 PROTEIN, HUMAN; STAT2 PROTEIN, HUMAN; TYRPHOSTIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; DOSE RESPONSE; DOWN REGULATION; HELA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION; CELL PROLIFERATION; DRUG EFFECT; METABOLISM; STRUCTURE ACTIVITY RELATION;

APOPTOSIS; BUTADIENES; CELL PROLIFERATION; HELA CELLS; HUMANS; NITRILES; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TYRPHOSTINS;

EID: 77649199328     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.1170/133     Document Type: Article

References (39)

1. Auernhammer, C.J., Dorn, F., Vlotides, G., Hengge, S., Kopp, F.B., Spoettl, G., Cengic, N., Engelhardt, D. and Weber, M.M., The oncostatin M receptor/gp130 ligand murine oncostatin M induces apoptosis in adrenocortical Y-1 tumor cells. J. Endocrinol. 2004, 180: 479-864.
2. Boulton, T.G., Nye, S.H., Robbins, D.J, Nancy, Y.I, Radzlejewska, E., Sharon, D.M., Ronald, A.D., Nikos, P., Melanie, H.C. and George, D.Y., ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991,65:663-675.
3. Chmidt, C.M., Wang, Y. and Wiesenauer, C., Novel combination of a COX-2 inhibitor, NS398, and MEK inhibitor, U0126, in human hepatocellular carcinoma provides synergistic increase in apoptosis. J. Gastrointest Surg. 2003, 7:1024-1033.
4. D'Amico, T.A. and Harpole, D.H., Molecular biology of esophageal cancer. Chest Surg Clin N Am. 2000, 10:451-469.
5. deFazio, A., Chiew, Y.E., Sini, R.L., Janes, P.W. and Sutherl, R.L., Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. In: J.Cancer. 2000,87: 487-498.
6. Derijard, B., Hibi, M., Wu, I.H., Barrett, T., Su, B., Deng, T.L., Karin, M. and Davis, R.J., JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994, 76:1025-1037.
7. Elahi, A., Zhang, L.,Yeatman, T.J., Gery, S., Sebti, S. and Shibata, D., HPP1-mediated tumor suppression requires activation of STAT1 pathways. In: J. Cancer 2008, 122:1567-1572.
8. Favata, M.F., Horiuchi, K.Y., Manos, E.J., Daulerio, A.J., Stradley, D.A., Feeser, W.S., Van, Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F., Copeland, R.A., Maqolda, R.L., Scherle, P.A. and Trzaskos, J.M., Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 1998, 273:18623-18632.
9. Gamero, A.M. and Larner, A.C., Vanadate facilitates interferon alpha-mediated apoptosis that is dependent on the Jak/Stat pathway. J. Biol. Chem. 2001,276: 13547-13553.
10. Han, J., Lee, J.D., Bibbs, L. and Ulevitch, R.J., A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Sci. 1994, 265: 808-811.
11. Haybaeck, J., Obrist, P., Schindler, C.U., Spizzo, G. and Doppler, W., STAT-1 expression in human glioblastoma and peritumoral tissue. Anticancer Res. 2007, 27:3829-3835.
12. Hellstrom,I., Goodman, G.,Pullman, J., Ynag, Y. and Hellstrom, K.E., Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 2001,61:2420-2423.
13. Hotokezaka, H., Sakai, E., Kanaoka, K., Saitor, K., Matsuo, K., Kitaura, H., Yoshida, N. and Nakayama, K., U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J. Biol. Chem. 2002, 277:47366-47372.
14. Huang, C., Liu, L.Y., Song, T.S., Ni, L., Song, L.P. and Si, L.S., Small interfering RNA-mediated MAPK p42 silencing induces apoptosis of HeLa cells. Nan Fang Yi Ke Da Xue Xue Bao. 2006,26:11-15.
15. Huang, C., Liu, L., Li, Z., Song, T.S., Ni, L. and Song, L.P., Effects of Small interfering RNAs targeting MAPK1 on gene expression profile in HeLa cells as revealed by microarray analysis. Cell. Biol. Int. 2008, 32:1081-1090.
16. Huang, D., Ding, Y., Luo, W.M., Bender, S., Qian, C.N., Kort, E., Zhang, Z.F., Kristin, V.B., Duesbery, N.S., James, H.R. and The, B.T., Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res.2008,68:81-88.
17. Imaizumi, M., Nishimura, M., Takeuchi, S., Murase, M. and Hamaguchi, M., Role of tyrosine specific phosphorylation of cellular proteins, especially EGF receptor and p125FAK in human lung cancer cells. Lung Cance.1997,17:69-84.
18. Janjua, S., Stephanou, A. and Latchman, D.S., The C-terminal activation domain of the STAT-1 transcription factor is necessary and sufficient for stress-induced apoptosis. Cell. Death.Differ. 2002, 9:1140-1146.
19. Kaplan, D.H., Shankaran, V., Dighe, A.S., Stochert, E., Aguet, M., Old, L.J. and Schreiber, R.D., Demonstration of an interferon gamma-dependent tumor surveillance system in immuno competent mice, Proc. Natl. Acad. Sci. USA. 1998,95: 7556-7561.
20. Kyriakis, J.M, and Avruch, J., Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol.Rev. 2001,81: 807-869.
21. Liu, L., Huang, C., Li, Z., Song, T.S. and Ni, L., Related genes for HeLa cell apoptosis induced by siRNA-mediated MAPK p42 silencing. Acta. Med. Univ. Sci. Technol. Huazhong. 2008,37:129-132.
22. Loucks, F.A., Le, S.S., Zimmermann, A.K., Angela, K.Z., Kristen, R.R., Holger, B., Klaus, A. and Daniel, A.L., Rho family GTPase inhibition reveals opposing effects of mitogen-activated protein kinase kinase/extracellular signal-regulated kinase and Janus kinase/signal transducer and activator of transcription signaling cascades on neuronal survival. J. Neurochem. 2006, 97:957-967.
23. Mascareno, E., Beckles, D.L., Siddiqui, M.A.Q., Janus kinase-2 signaling mediates apoptosis in rat cardiomyocytes. Vasc Pharmacol 2005, 43:327-335.
24. Negoro, S., Kunisada, K., Tone, E., Funamoto, M., Oh, H., Kishimoto, T. and Keiko, Y.T., Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc. Res. 2000,47:797-805.
25. Rolitsky, C.D., Theil, K.S., McGaughy, V.R., Copeland,L.J. and Niemann,T.H., HER-2/neu amplification and overexpression in endometrial carcinoma. Int. J. Gynecol. Pathol. 1999, 18:138-143.
26. Sandberg, E.M., Ma, X., VonDerLinden, D., Godeny, M.D. and Sayeski, P.P., Jak2 tyrosine kinase mediates angiotensin II-dependent inactivation of ERK2 via induction of mitogen-activated protein kinase phosphatase 1. J. Biol. Chem. 2004, 279:1956-1967.
27. Scoccia, B., Lee, Y.M., Niederberger, C. and Ilekis,J.V., Expression of the ErbB family of receptors in ovarian cancer. J. Soc. Gynecol. Investig. 1998, 5: 161-165.
28. Sebolt-Leopold, J.S. and Herrera, R., Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer. 2004, 4:937-947.
29. Seger, R. and Krebs, E.G., The MAPK signaling cascade. FASEB. J. 1995, 9: 726-735.
30. Simon, C., Hicks, M.J., Nemechek, A.J., Mehta, R., O'Malley, B.W. Jr, Goepfert, H., Flaitz, C.M. and Bovd, D., PD098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br. J. Cancer. 1999, 80:1412-1419.
31. Steinmetz, R., Wagoner, H.A., Zeng, P., Hammond, J.R., Hannon, T.S., Meyers, J.L. and Pescovtz, O.H., Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol. Endocrinol. 2004, 18:2570-2582.
32. Townsend, P.A., Scarabelli, T.M., Davidson, S.M., Knight, R.A., Latchman, D.S. and Stephanou, A., STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J. Biol. Chem. 2004, 279:5811-5820.
33. Townsend PA, Cragg MS, Davidson SM, Knight, R.A., Latchman, D.S. and Stephanou, A., STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J. Cell. Sci. 2005, 118:1629-1639.
34. Tuziak, T., Olszewski, W.P., Olszewski, W. and Plenkowski, T. Expression of HER2/neu in primary and metastatic breast cancer. Pol. J. Pathol. 2001,52:21-26.
35. van der Valk, P., Lindeman, J. and Kamphorst, W., Growth factor profiles of human gliomas. Do non-tumour cells contribute to tumour growth in glioma? Ann. Oncol. 1997, 8: 1023-1029.
36. Wiesenauer, C.A., Yip-Schneider, M.T., Wang, Y. and Schmidt, C.M., Multiple Anticancer Effects of Blocking MEK-ERK Signaling in Hepatocellular Carcinoma. J. Am. Coll. Surg. 2004, 198:410-421.
37. Yang, J. and Stark, G.R., Roles of unphosphorylated STATs in signaling. Cell. Res. 2008, 18:443-451.
38. Youlyouz-Marfak, I., Gachard, N., Le Clorennec, C., Najjar, I., Baran-Marszak, F., R eminieras, L., May, E., Bornkamm, G.W., Fagard, R. and Feuillard, J., Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell. Death. Differ. 2008, 15:376-385.
39. Zhang, S., Li, Z., Wu, X., Huang, Q., Shen, H.M. and Ong, C.N., Methyl-3-indolylacetate inhibits cancer cell invasion by targeting the MEK1/2-ERK1/2 signaling pathway. Mol. Cancer. Ther. 2006, 5:3285-3293.